Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00048945 |
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B |
Drug: PEGASYS |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | WV16240 |
Study First Received: | November 12, 2002 |
Last Updated: | August 11, 2005 |
ClinicalTrials.gov Identifier: | NCT00048945 |
Health Authority: | United States: Food and Drug Administration |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Chronic |
Hepatitis B, Chronic Hepatitis B Peginterferon alfa-2a Hepatitis, Viral, Human DNA Virus Infections |
Anti-Infective Agents Therapeutic Uses Antiviral Agents Hepadnaviridae Infections Pharmacologic Actions |